Skip to Main content Skip to Navigation
Journal articles

Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant.

Abstract : Obesity, currently associated with metabolic syndrome is characterized by an excessive fat storage in different organs, in particular adipose tissue, inducing the loss of its structural and functional integrity. Being aware of the importance of adipose tissue endocrine function and the key role of adipocytokines, such as adiponectin, in obesity and metabolic syndrome drives the necessity to develop new drugs that can exert a specific action on adipose tissue and on adiponectin levels. Rimonabant, an antiobesity drug, presents a dual effect by decreasing food intake and importantly increasing adiponectin. This review focuses on the key role of adiponectin regulation in the success of rimonabant and suggests that this adipohormone may be considered as a therapeutic target to design innovative and promising antiobesity and anti-metabolic syndrome drugs.
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00338419
Contributor : Yves Le Ster <>
Submitted on : Thursday, November 13, 2008 - 10:52:34 AM
Last modification on : Wednesday, October 3, 2018 - 4:02:04 PM
Long-term archiving on: : Monday, June 7, 2010 - 9:21:54 PM

Identifiers

Collections

Citation

Marie Maynadier, Ilaria Basile, Magali Gary-Bobo. Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant.. Drug Discovery Today, Elsevier, 2009, 14 (3-4), pp.192-7. ⟨10.1016/j.drudis.2008.09.009⟩. ⟨inserm-00338419⟩

Share

Metrics

Record views

453

Files downloads

1595